Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigil Vaccine + Chemotherapy in Colorectal Cancer with Liver Metastases
NCT01505166Phase 2Terminated
- Sponsor
- Gradalis, Inc.
- Start
- Mar 2012
- Primary completion
- Aug 2016
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA), Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of gemogenovatucel-T in colorectal carcinoma (CRC), sponsored by Gradalis, Inc.. Started Mar 2012; status: terminated.
02
Drugs
gemogenovatucel-T
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT01505166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01505166.